Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir.Clausen, D.J., Liu, J., Yu, W., Duffy, J.L., Chung, C.C., Myers, R.W., Klein, D.J., Fells, J., Holloway, K., Wu, J., Wu, G., Howell, B.J., Barnard, R.J.O., Kozlowski, J.
(2020) Bioorg Med Chem Lett 30: 127367-127367
- PubMed: 32738976
- DOI: https://doi.org/10.1016/j.bmcl.2020.127367
- Primary Citation of Related Structures:
- PubMed Abstract:
The synthesis and SAR development of a trisubstituted imidazole HDAC inhibitor is described. The compounds were synthesized with high diastereocontrol by leveraging Ellman sulfinyl imine chemistry. Structural elucidation provided insight into binding mode and supported design rational. Pharmacokinetic properties of lead compounds were determined.
Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA.